X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospectrumasia.com/news/25/24109/korean-firm-hyundai-bioscience-soon-to-initiate-global-clinical-development-on-dengue-antiviral-candidate.html
https://www.globenewswire.com/news-release/2022/03/28/2411405/0/en/First-Wave-BioPharma-Files-U-S-and-PCT-Patent-Applications-for-Niclosamide-in-Long-Haul-COVID-19.html
https://www.globenewswire.com/news-release/2022/02/24/2391586/0/en/TFF-Pharmaceuticals-Announces-Inhaled-Niclosamide-Significantly-Inhibits-Viral-Replication-of-the-Omicron-Variant-of-SARS-CoV-2.html
https://www.globenewswire.com/news-release/2022/01/27/2374302/0/en/TFF-Pharmaceuticals-Completes-Enrollment-in-Phase-1-Study-Evaluating-Inhaled-Formulation-of-Niclosamide-to-Treat-COVID-19.html
https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-enrollment-of-first-patient-in-the-prevent-study-evaluating-niclosamide,c3438458
https://www.globenewswire.com/news-release/2021/10/21/2318239/0/en/First-Wave-BioPharma-Forms-Steering-Committee-for-Phase-2a-PASSPORT-Clinical-Trial-to-Evaluate-FW-ICI-AC-in-Cancer-Patients-with-Immune-Checkpoint-Inhibitor-Associated-Colitis.html
https://www.globenewswire.com/news-release/2021/10/14/2314372/0/en/First-Wave-BioPharma-Announces-Dosing-of-First-Patient-in-Phase-2b-Clinical-Trial-Evaluating-Topical-Niclosamide-in-Patients-with-Ulcerative-Proctitis-and-Ulcerative-Proctosigmoidi.html
https://www.biospace.com/article/releases/neurobo-pharmaceuticals-announces-positive-recommendation-from-independent-data-safety-monitoring-committee-of-phase-2-3-clinical-trial-of-ana001-in-hospitalized-patients-with-moderate-to-severe-covid-19/?s=71
https://www.globenewswire.com/news-release/2021/09/28/2304403/0/en/First-Wave-BioPharma-Begins-Patient-Screening-for-Phase-2b-Clinical-Trial-Evaluating-Niclosamide-in-Patients-with-Ulcerative-Proctitis-and-Ulcerative-Proctosigmoiditis.html
https://www.globenewswire.com/news-release/2021/09/09/2294333/0/en/AzurRx-BioPharma-Announces-Positive-Results-from-Independent-Data-Monitoring-Committee-Review-of-Safety-Data-from-Part-1-of-RESERVOIR-Phase-2-Clinical-Trial-of-Niclosamide-for-the-.html
https://www.biospace.com/article/releases/azurrx-biopharma-submits-an-investigational-new-drug-application-for-niclosamide-as-treatment-for-grade-1-and-grade-2-immune-checkpoint-inhibitor-/?s=71
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/phase-ii-clinical-trial-of-niclosamide-drug-for-treatment-of-covid-19-patients-begins/articleshow/83282880.cms
https://en.prnasia.com/releases/global/hyundai-bioscience-leads-in-the-repurposing-of-niclosamide-314329.shtml
https://www.clinicaltrialsarena.com/news/union-therapeutics-endpoints-trial/
https://en.prnasia.com/releases/global/hyundai-bioscience-leads-in-the-repurposing-of-niclosamide-314329.shtml
https://www.globenewswire.com/news-release/2021/01/04/2152518/0/en/AzurRx-BioPharma-Announces-Exclusive-Worldwide-License-Agreement-with-First-Wave-Bio-for-Use-of-Proprietary-Niclosamide-Formulations-to-Treat-Immune-Checkpoint-Inhibitor-Associated.html
https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-et-tufts-medical-center-joignent-leurs-forces-pour-la-phase-2-des-essais-cliniques-du-niclosamide-pour-la-covid-19-817333364.html
https://en.prnasia.com/releases/global/daewoong-pharmaceutical-partners-with-tufts-medical-center-for-phase-2-clinical-trial-with-niclosamide-296667.shtml
https://www.prnewswire.com/news-releases/danish-biotech-union-adds-program-to-prevent-covid-19-with-intranasal-delivery-of-niclosamide-301156611.html
http://www.koreaherald.com/view.php?ud=20201012000451
https://www.prnewswire.com/news-releases/union-therapeutics-as-completes-dosing-of-healthy-volunteers-with-uni911-inhaled-niclosamide-for-covid-19-301117470.html
https://www.contractpharma.com/contents/view_breaking-news/2020-08-17/tff-pharmaceuticals-signs-worldwide-licensing-agreement-with-union-therapeutics/
https://www.prnewswire.com/news-releases/union-therapeutics-as-enters-option-agreement-to-acquire-worldwide-exclusive-license-for-covid-19-technologies-developed-by-tff-pharmaceuticals-inc-301112201.html
https://www.quotientsciences.com/news/ana-therapeutics-and-quotient-sciences-announce-pa/
https://www.prnewswire.com/news-releases/ana-therapeutics-announces-us-fda-clearance-of-ind-application-to-initiate-clinical-trial-of-niclosamide-in-covid-19-patients-301105314.html
https://www.prnewswire.co.uk/news-releases/union-receives-approval-from-danish-medicines-agency-to-initiate-clinical-study-with-niclosamide-for-treatment-of-covid-19-870178027.html
https://www.pharmaceutical-technology.com/news/daewoong-niclosamide-animal-data/
http://www.koreaherald.com/view.php?ud=20200605000614
https://www.newswire.com/news/union-therapeutics-launches-covid-19-program-in-collaboration-with-21127619
http://www.biospace.com/News/merus-buys-four-products-from-sanofi-for-22-5/409604/source=TopBreaking
Market Place
Share 
